Prostate cancer, version 1.2014 Journal Article
| Authors: | Mohler, J. L.; Kantoff, P. W.; Armstrong, A. J.; Bahnson, R. R.; Cohen, M.; D'Amico, A. V.; Eastham, J. A.; Enke, C. A.; Farrington, T. A.; Higano, C. S.; Horwitz, E. M.; Kawachi, M. H.; Kuettel, M.; Lee, R. J.; MacVicar, G. R.; Malcolm, A. W.; Miller, D.; Plimack, E. R.; Pow-Sang, J. M.; Richey, S.; Roach, M. 3rd; Rohren, E.; Rosenfeld, S.; Small, E. J.; Srinivas, S.; Stein, C.; Strope, S. A.; Tward, J.; Walsh, P. C.; Shead, D. A.; Ho, M. |
| Article Title: | Prostate cancer, version 1.2014 |
| Abstract: | The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings. © National Comprehensive Cancer Network, Inc. All rights reserved. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 11 |
| Issue: | 12 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2013-12-01 |
| Start Page: | 1471 |
| End Page: | 1479 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 24335682 |
| DOI/URL: | |
| Notes: | Export Date: 3 February 2014 -- Source: Scopus |
